Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05278182
Other study ID # CRFH20180010
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 2022
Est. completion date June 30, 2025

Study information

Verified date May 2022
Source Chinese Academy of Medical Sciences, Fuwai Hospital
Contact Qian Jie
Phone +86 13601396650
Email qianjfw@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate and compare the change of plaque composition by VH-IVUS imaging in subjects who take NXT and placebo in post-PCI of AMI patients during 12 months follow-up.


Description:

NXT-ASSESS is a placebo controlled,double-blind,randomised trial for assessment of the efficacy of Naoxingtong capsules in the treatment of coronary atherosclerotic plaque in patients with acute myocardial infarct on the basis of optimal medical therapy.A total of approximately 80 AMI patients with selective PCI indication who take NXT and placebo in post-PCI 12 months


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date June 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Signing informed consent; 2. Male or female aged 18 to 75 years old; 3. AMI patients with selective PCI indication primary PCI patients are exclusive; 4. No history of CABG or PCI; Image inclusion criteria: 1. CCTA at least one in-segment =20% and =70% diameter stenosis non-culprit vessel in the proximal-middle segments of RCA, LCX, LAD (the proximal and distal plaque within 5mm, same as below); 2. Radiography diameter of target vessel, 2.5-4.0mm; 3. Studied vessel can be evaluated with OCT and IVUS; OCT: the visual target study lesion is lipid-rich plaque with lipid arc=100 degree and fiber cap thickness=120µm. Exclusion Criteria: 1. Life expectancy is less than 1 year; 2. Cannot implant drug stent; 3. Received =4weeks systematic treatment of statin and other lipid-lowering drug in the 3 months before admission; 4. Received =4 weeks systematic treatment of any traditional Chinese medicine; 5. Known to have adverse reaction to ingredients of NXT capsule; 6. Patients with severe heart disease that CABG or selective PCI, heart transplantationSAVR/TAVR are required during the study(12 months); 7. LVEF<40%; 8. Drug uncontrollable recurrent and highly symptomatic arrhythmia such as ventricular tachycaidia, atrial fibrillation with rapid ventricular rate and paroxysmal supraventricular tachycardia in the 3 months before ACS admission; 9. Known any stroke; 10. Other operations arranged during the study period (12 months); 11. Uncontrollable hypertension, defined as resting systolic BP=180mmHg; 12. Clinical confirmed as statin intolerance; 13. Type I diabetes or type 2 diabetes that is not well controlled; 14. Moderate and severe renal dysfunction (defined as eGFR<30ml/min/1.73m2); 15. Clinical confirmed liver disease or liver dysfunction (AST or ALT >3*ULN); 16. Clinical confirmed infection and other hematological, metabolic gastrointestinal or endocrine dysfunction that researchers believe not suitable for enrollment; 17. Known factors that may not be compliant, such as alcoholism, drug addiction, mental illness, etc.; 18. Participated in other clinical research projects, or within 30 days of the last participating clinical project; 19. Pregnant,breast feeding women or those plan to conceive during the study; 20. History of malignant tumor. Lesion related: 1. Target segment severe calcification; 2. Failed PCI in culprit vessel; 3. Failed OCT screening (lipid arc/ fiber cap thickness does not match filter criteria); 4. Complications during the evaluation of OCT and IVUS/VH-IVUSOCT and IVUS/VH-IVUS evaluation failed due to instruments.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Naoxintong Capsule
Patients with acute myocardial infarct on the basis of optimal medical therapy will take Naoxintong capsules following directions for 12 months
Placebo
Patients with acute myocardial infarct on the basis of optimal medical therapy will take placebo following directions for 12 months

Locations

Country Name City State
China Chinese Academy of Medical Sciences, Fuwai Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Chinese Academy of Medical Sciences, Fuwai Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plaque composition The change of plaque composition by virtual histology intravascular ultrasound imaging in subjects who take Naoxintong capsules and placebo in post-percutaneous coronary intervention follow-up 12 months
Primary Plaque fibrous cap thickness The change of plaque fibrous cap thickness measured by optical coherence tomography in subjects who take Naoxintong capsules and placebo during post-percutaneous coronary intervention follow-up 12 months
Secondary Lipid arc The change of lipid arc measured by optical coherence tomography in subjects who take Naoxintong capsules and placebo in post-percutaneous coronary intervention follow-up 12 months
Secondary Percent atheroma volume The change of percent atheroma volume measured by intravascular ultrasound imaging in subjects who take Naoxintong capsules and placebo capsules during post-percutaneous coronary intervention follow-up 12 months
Secondary Total atheroma volume and low attenuation plaque volume Total atheroma volume and low attenuation plaque volume measured by Coronary-CTA in subjects who take Naoxintong and placebo capsules during post-percutaneous coronary intervention follow-up 12 months
Secondary Lipid The change of lipid measured by optical coherence tomography in subjects who take Naoxintong capsules 12 months
Secondary Platelet function The change of platelet function measured by optical coherence tomography in subjects who take Naoxintong capsules 12 months
Secondary Clinical incidents The number of clinical incidents in subjects who take Naoxintong capsules 12 months
Secondary Culprit vessel The change of subjects culprit vessel with optical coherence tomography; 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT01572259 - Assessment of the Role of the Growth Hormone (GH) Onthe Intestinal Triglyceride-rich-lipoproteins (TRL) Metabolism Phase 3
Completed NCT05792787 - Association Between Apical Periodontitis and Atherosclerotic Cardiovascular Diseases
Completed NCT03911284 - The Learning Registry
Recruiting NCT06048588 - YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis Phase 1/Phase 2
Active, not recruiting NCT03705234 - A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease Phase 3
Completed NCT03096288 - Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity Phase 4
Enrolling by invitation NCT05485961 - Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis Phase 2/Phase 3
Completed NCT01663402 - ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab Phase 3
Completed NCT03597412 - Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM Phase 4
Completed NCT05974345 - In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Active, not recruiting NCT05030428 - Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease Phase 3
Completed NCT00185185 - Olmesartan Medoxomil in Atherosclerosis Phase 3
Completed NCT05129241 - Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector
Completed NCT02991118 - Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Phase 3
Completed NCT05639244 - Time Restricted Eating and Innate Immunity N/A
Completed NCT02988115 - Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant Phase 3
Recruiting NCT04215237 - How Atorvastatin Affects the Gut Flora and Metabolomics? N/A
Completed NCT05355402 - A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia Phase 2
Recruiting NCT05726838 - The Belgian REAL (BE.REAL) Registry
Active, not recruiting NCT04462159 - The Young Heart Study N/A